Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25895105 | 0.80 | TOP2A (0.39) | — | |
| SCHEMBL24770546 | 0.77 | — | — | |
| SCHEMBL23989433 | 0.77 | ALDH1A1 (0.35) | TDP1ALDH1A1LMNAALOX15MPO | |
| SCHEMBL10274589 | 0.76 | — | — | |
| SCHEMBL30755587 | 0.76 | ALDH1A1 (0.34) | TDP1ALDH1A1LMNAALOX15MPO | |
| SCHEMBL25864821 | 0.74 | TOP2A (0.30) | — | |
| Bromide SCHEMBL6855980 | 0.74 | CHRM2 (0.38) | — | |
| SCHEMBL24769807 | 0.73 | — | — | |
| SCHEMBL23989358 | 0.73 | CASR (0.34) | TDP1ALDH1A1LMNAALOX15MPO | |
| SCHEMBL31728494 | 0.71 | ALDH1A1 (0.33) | TDP1ALDH1A1LMNAALOX15MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | TDP1 3424/4885ALDH1A1 164/4885LMNA 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.